

Rheumatoid Arthritis

Chronic inflammatory disease

Autoimmune disease

Autoimmunity

Reactivity to self-antigens

—immune dysregulation

Autoimmune Disease

Autoreactivity leading to



tissue inflammation and damage


occurring in absence of ongoing infection






Epidemiology

- Worldwide– Overall 1% prevalence
- Female:Male 2-3 : 1
- Age of onset 30's-50's





Pannus




PIP swelling



Ulnar deviation, MCP swelling
left wrist swelling



Bouteniere's and swan neck
deformities



Bony erosion

Clinical Manifestations

Arthritis

Inflammatory

Symmetric

Pattern:

small joints of the hands and feet
wrists ankles

knees

elbows

hips

cervical spine

Clinical Manifestations

Extra-articular

Constitutional symptoms

Rheumatoid nodules

Pulmonary involvement

Ocular involvement

Cardiac involvement

Vasculitis


Extraarticular manefestations

Rheumatoid nodules



Extra-articular manifestations

- Pulmonary manifestations
 - Pulmonary nodules
 - Pleuritis
 - Interstitial lung disease
 - Interstitial alveolitis



Extra-articular manifestations

- Ophthalmologic manifestations
 - Dry eyes/Sjogren's syndrome
 - Inflammatory eye disease
 - Episcleritis
 - Scleritis
 - Uveitis
 - Corneal melt



Extra-articular manifestations



- Cardiac involvement
 - Pericarditis
- Vasculitis
 - Skin ulcerations
 - Palpable purpura
 - Mononeuritis multiplex



Clinical Manifestations

Associated syndromes

Sjogren's Syndrome



Felty's Syndrome

Seropositive Rheumatoid Arthritis
Splenomegaly
Granulocytopenia

Pathogenesis

Genetic factors

Environmental factors

Immune dysregulation

Autoimmune disease


Genetic factors

- HLA shared epitope
- Peptidylarginine deiminase (PADI4) (J)
Forms citrulline from Arg residues in proteins
- PTPN22 (EU)
Hematopoietic-specific protein tyrosine phosphatase gene
- MHC2TA promotor
MHC Class II transactivator, a major transcription factor for MHC Class II and other genes
- FCRL3 (J)
Fc receptor-like 3
- CTLA4 (Asian)
- IL5R, IL2, IL4, IL1RA, IFN- γ , IL10 p, MBL, PD-1, PDCD-1

HLA DRB1 Alleles Associated with RA


Associated alleles	67	68	69	70	71	72	73	74
DRB1*0401	Leu			Glu	Lys			Ala
DRB1*0404	Leu			Glu	Arg			Ala
DRB1*0101	Leu			Glu	Arg			Ala
Non-associated allele								
DRB1*1402	Ile			Asp	Glu			

Amino acid sequences in the β chain HLA-DRB*0401 molecules dictate susceptibility to RA




Pathogenesis


Initiating Event in Rheumatoid Arthritis




Antigen Recognition and Costimulation




CD4+ T Cells Differentiate into Distinct T_H1 and T_H2 Subsets




Consequences of CD4+ T_H1 mediated autoimmunity:






Immunopathophysiology of Rheumatoid Arthritis



Inflammatory cytokine disequilibrium in Rheumatoid arthritis








Rheumatoid factor


- Recognizes Fc portion of IgG
- Typically IgM, but may be IgG, IgA, IgE
- 80% of RA patients
- Not specific for RA, seen in other rheumatic conditions as well as chronic inflammatory conditions (TB, SBE)
- Biologic and Pathologic Functions of RF's
 - Augment phagocytosis of opsonized particles
 - Immune complex clearance
 - RF bound to IgG or to immune complexes can precipitate in vessel walls and induce vasculitis. High titer RF is associated with systemic vasculitis in RA
 - Rheumatoid factors bind to Fc γ receptors on macrophages and augment the release of cytokines, including IL-1 and TNF- α

Anti-CCP

- Recognizes citrullinated proteins
- Precedes development of RA by years
- 80% sensitivity, 98% specificity in RA
- Modulation of erosive arthritis in animal models



Immunopathophysiology of Rheumatoid Arthritis



Treatment of Rheumatoid Arthritis

Inhibit products of T cells and macrophages

NSAIDs, TNF inhibition, IL-1 receptor inhibitors

Prevent T cell, B cell or synovial cell proliferation

Methotrexate, Azathioprine, Leflunomide

Decrease T cell activation

Cyclosporin


Inhibit T cell or APC function

Corticosteroids, gold, penicillamine

Potential Treatment of Rheumatoid Arthritis

- Block T cell activation

Blockade of T cell activation by costimulation antagonists



Potential Treatments of Rheumatoid Arthritis

- **Block T cell activation**
Anti-CD40L, CTLA4-Ig
- **B cell depletion**
Anti-CD20 antibody--Rituximab